Schrödinger’s Q2 Playbook: SDGR’s ACV Accelerates, Margin Moves to Hosted, and Milestones Fuel the Forecast

Schrödinger, Inc. (Nasdaq: SDGR) reported second-quarter 2026 results that underscore a business model pivot and a cash-rich backdrop. The earnings snapshot features a GAAP net income of $6.0 million, a dramatic swing from a $43.2 million quarterly loss a year ago, and EPS implications that investors will soon map against EPS consensus estimates. The company also reiterated its revenue trajectory, including an ACV (annual contract value) trajectory of about $29.6 million for Q2 (the press release cites a $30 million figure in headlines), with trailing four-quarter ACV near $208 million. Schrödinger’s release throws light on how it is stitching together software and drug discovery revenue as it moves toward hosted licensing, while management touts a growth narrative grounded in collaboration milestones and operating leverage.

Key quarterly highlights

ACV growth: Q2 ACV of $29.6 million, up 27% year over year; trailing four-quarter ACV around $208 million.
Revenue mix: Total revenue of $58.9 million, up 8%; software revenue of $32.5 million, down 10% as the company accelerates hosted software licensing (hosted revenue comprising 47% of software revenue; 30% on a trailing four-quarter basis).
Drug discovery revenue: $23.0 million, up from $13.9 million, driven by a $10 million collaboration milestone tied to Ajax Therapeutics.
Contribution revenue / cost of revenue: $3.4 million, down from $4.8 million due to timing of grants; revenue by segment reclassifications noted to improve comparability.
Other income: $48.9 million, largely from a gain related to Eli Lilly’s acquisition of Ajax Therapeutics.
Profitability: Net income of $6.0 million; the company emphasizes the top-line strength and the notable one-time gains rather than ongoing operating profit alone.
Balance sheet: Cash, cash equivalents, restricted cash and marketable securities of $418.8 million.

Management reiterates Schrödinger’s practice of presenting contribution revenue and cost of revenue separately from software and drug-discovery lines, with prior periods reclassified to improve year-over-year comparability.

Management commentary and strategic posture

In a tone befitting a company selling predictive data to drug developers, Ramy Farid, Ph.D., Schrödinger’s CEO, framed the quarter as validation of a “predict-first” approach. He highlighted the continued convergence of physics-based simulations with AI, and the launch of Bunsen, the agentic AI co-scientist for molecular discovery, as a catalyst for larger-scale, repeatable workflows. The quote lands in the public record as a reminder that the business is as much about data infrastructure as it is about pipelines and milestones. In Levine-ian terms, the company is trying to turn a data moat into a product moat—and the moat is widening as customers pay for more hosted capabilities and milestone-driven revenue streams.

Outlook and revenue forecast

Schrödinger provided a forward-looking view as of August 5, 2026: ACV is expected to range from $218 million to $228 million for the year, representing 10–15% growth versus 2025. Drug discovery revenue is guided to $65 million–$75 million, an upgrade from prior expectations of $55 million–$65 million, aided by the $10 million collaboration milestone tied to Ajax. The combination of higher drug-discovery revenue guidance and a resilient software trajectory underpins a cautiously constructive revenue forecast narrative for the balance of 2026.

What this might portend for SDGR and peers

The quarterly mix—strong ACV growth, a shift toward hosted software licensing, and a critical milestone-driven revenue engine—highlights a model where software discipline is increasingly the backbone of life sciences revenue. The outsized impact of non-operating gains (the Ajax/Lilly interaction) on net income introduces a caveat: GAAP earnings may be less about operational leverage this quarter and more about grant timing and equity investments’ fair value fluctuations. Still, the operating expense line shows discipline: expenses declined 6% year over year, which matters for margin expansion if hosted software revenue catches up and the hosted model fundamentally scales.

For sector peers, Schrödinger’s trajectory signals a premium for milestones and collaboration-based revenue, especially when combined with a clear hosted licensing strategy. If the market assigns value to the margin profile of hosted software and the durability of ACV growth, stocks in this space may re-rate on EPS quality and earnings surprise potential, even as quarterly GAAP earnings remain sensitive to one-time gains and grant-driven adjustments. In short, expected EPS consensus could hinge more on the durability of software gross margins and recurring revenue than on any single milestone, which makes the upcoming quarterly reports a litmus test for the industry’s shift toward platform-like, automated discovery tools.

Bottom line

Schrödinger’s Q2 2026 results present a coherent narrative: growing ACV, a meaningful shift to hosted software licensing, and a favorable-but-mixed bag of drivers like collaboration milestones and non-operating gains. The 2026 revenue forecast, particularly the uplift in drug discovery revenue guidance, aligns with a strategy that monetizes both AI-enabled discovery and data infrastructure. For investors stalking EPS expectations, the near-term path will depend on how the company translates this quarter’s non-operating windfalls into sustainable earnings per share and how well the hosted-revenue engine can broaden gross margins over time. If the market prices in the higher guidance and the respectable cash balance, SDGR could see a steadier, more durable earnings trajectory even as it navigates the inevitable volatility of milestone-driven revenue streams.